Share
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Manage episode 478868102 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In today’s episode, we had the pleasure of speaking with Daniel P. Petrylak, MD, about Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in metastatic castration-resistant prostate cancer (mCRPC). Dr Petrylak is a professor of medicine (medical oncology) and urology, as well as the chief of Genitourinary Oncology, at Yale School of Medicine and Smilow Cancer Hospital in New Haven, Connecticut.
In our exclusive interview, Dr Petrylak discussed the current role for Pluvicto in patients with mCRPC, the safety profile of this radiotherapeutic, the importance of multidisciplinary collaboration when delivering this therapy, and future directions for investigating radioligand therapies in combination with other classes of agents.
In our exclusive interview, Dr Petrylak discussed the current role for Pluvicto in patients with mCRPC, the safety profile of this radiotherapeutic, the importance of multidisciplinary collaboration when delivering this therapy, and future directions for investigating radioligand therapies in combination with other classes of agents.
642 episodes
))
